Tandospiron

Iz Wikipedije, slobodne enciklopedije
Tandospiron
(IUPAC) ime
(1R,2R,6S,7S)-44-[4-(pirimidin-2-il)piperazin-1-il]butil4-azatriciklo[5.2.1.02,6]dekan-3,5-dion
Klinički podaci
AHFS/Drugs.com Internacionalno ime leka
Identifikatori
CAS broj 112457-95-1
ATC kod nije dodeljen
PubChem[1][2] 91273
ChemSpider[3] 82421
UNII 190230I669 YesY
ChEMBL[4] CHEMBL274047 YesY
Hemijski podaci
Formula C21H29N5O2 
Mol. masa 383,487 g/mol
SMILES eMolekuli & PubHem
Farmakokinetički podaci
Poluvreme eliminacije 1,2–1,4 sata
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status Prescription only
Način primene Oralno

Tandospiron (Sediel, metanopiron) je anksiolitik i antidepresiv koji se koristi u Kini i Japanu. On je član azapironske i piperazinske hemijske klase, i blisko je srodan sa drugim agensima poput buspirona i gepirona.

Farmakologija[uredi - уреди | uredi izvor]

Tandospiron deluje kao potentan i selektivan parcijalni agonist 5-HT1A receptora, sa Ki afinitetom od 27 ± 5 nM[5] i aproksimativno 55-85% intrinsične aktivnosti.[6][7] On ima slab i klinički zanemarljiv afinitet za 5-HT2A (1,300 ± 200), 5-HT2C (2,600 ± 60), α1-adrenergički (1,600 ± 80), α2-adrenergički (1,900 ± 400), D1 (41,000 ± 10,000), i D2 (1,700 ± 300) receptore, i esencijalno je neaktivan na 5-HT1B, 5-HT1D, β-adrenergičkom, i muskarinskim acetilholinskim receptorima, serotoniskom transportertu (SERT), i benzodiazepinskom (BDZ) alosternom mestu GABAA receptora (svi od kojih su > 100.000).[5] Postoji evidencija da tandospiron ima nisku, mada značajnu antagonističku aktivnost na α2-adrenergičkom receptoru putem njegovog aktivnog metabolita 1-(2-pirimidinil)piperazin (1-PP).[8][9]

Hemija[uredi - уреди | uredi izvor]

Tandospiron se može sintetisati na sledeće način:[10]

Tandospirone synth.png

Reference[uredi - уреди | uredi izvor]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3.  edit
  4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.  edit
  5. 5,0 5,1 Hamik; Oksenberg, D; Fischette, C; Peroutka, SJ (1990). "Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites". Biological Psychiatry 28 (2): 99–109. PMID 1974152. doi:10.1016/0006-3223(90)90627-E. 
  6. Tanaka; Tatsuno, T; Shimizu, H; Hirose, A; Kumasaka, Y; Nakamura, M (1995). "Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain". General pharmacology 26 (8): 1765–72. PMID 8745167. doi:10.1016/0306-3623(95)00077-1. 
  7. Yabuuchi, Kazuki; Tagashira, Rie; Ohno, Yukihiro (2004). "Effects of tandospirone, a novel anxiolytic agent, on human 5-HT1A receptors expressed in Chinese hamster ovary cells (CHO cells)". Biogenic Amines 18 (3): 319. doi:10.1163/1569391041501933. 
  8. Blier; Curet, O; Chaput, Y; De Montigny, C (1991). "Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine--II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission". Neuropharmacology 30 (7): 691–701. PMID 1681447. doi:10.1016/0028-3908(91)90176-C. 
  9. Miller; Thompson, ML; Byrnes, JJ; Greenblatt, DJ; Shemer, A (1992). "Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine". Journal of Clinical Psychopharmacology 12 (5): 341–5. PMID 1362206. 
  10. Yevich, Joseph P.; New, James S.; Smith, David W.; Lobeck, Walter G.; Catt, John D.; Minielli, Joseph L.; Eison, Michael S.; Taylor, Duncan P.; Riblet, Leslie A. (1986). "Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents". Journal of Medicinal Chemistry 29 (3): 359–69. PMID 2869146. doi:10.1021/jm00153a010. 

Vidi još[uredi - уреди | uredi izvor]

Spoljašnje veze[uredi - уреди | uredi izvor]